title: Nanocalcium-deficient hydroxyapatite-poly (e-caprolactone)-polyethylene glycol-poly (e-caprolactone) composite scaffolds.
abstract: A bioactive composite of nano calcium-deficient apatite (n-CDAP) with an atom molar ratio of calcium to phosphate (Ca/P) of 1.50 and poly(ɛ-caprolactone)-poly(ethylene glycol)-poly(ɛ-caprolactone) (PCL-PEG-PCL) was synthesized, and a composite scaffold was fabricated. The composite scaffolds with 40 wt% n-CDAP contained well interconnected macropores around 400 μm, and exhibited a porosity of 75%. The weight-loss ratio of the n-CDAP/PCL-PEG-PCL was significantly greater than nano hydroxyapatite (n-HA, Ca/P = 1.67)/PCL-PEG-PCL composite scaffolds during soaking into phosphate-buffered saline (pH 7.4) for 70 days, indicating that n-CDAP-based composite had good degradability compared with n-HA. The viability ratio of MG-63 cells was significantly higher on n-CDAP than n-HA-based composite scaffolds at 3 and 5 days. In addition, the alkaline phosphatase activity of the MG-63 cells cultured on n-CDAP was higher than n-HA-based composite scaffolds at 7 days. Histological evaluation showed that the introduction of n-CDAP into PCL-PEG-PCL enhanced the efficiency of new bone formation when the composite scaffolds were implanted into rabbit bone defects. The results suggested that the n-CDAP-based composite exhibits good biocompatibility, biodegradation, and osteogenesis in vivo.
authors: Department of Orthopedics, Shanghai Hospital, Second Military Medical University, Shanghai, People's Republic of China.
authors: Zhiwei
authors: Z
authors: Wang
authors: Ming
authors: M
authors: Li
authors: Baoqing
authors: B
authors: Yu
authors: Liehu
authors: L
authors: Cao
authors: Qingsong
authors: Q
authors: Yang
authors: Jiacan
authors: J
authors: Su
mesh_terms: D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D018786:Bone Substitutes / Q000737:chemistry* / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D017886:Durapatite / Q000737:chemistry* / Q000494:pharmacology; D005269:Femur / Q000166:cytology / Q000293:injuries; D006651:Histocytochemistry; D006801:Humans; D008422:Materials Testing; D053761:Nanocomposites / Q000737:chemistry*; D010012:Osteogenesis / Q000187:drug effects; D010316:Particle Size; D011091:Polyesters / Q000737:chemistry* / Q000494:pharmacology; D011092:Polyethylene Glycols / Q000737:chemistry* / Q000494:pharmacology; D011817:Rabbits; D054457:Tissue Scaffolds / Q000737:chemistry*
chemical_list: D018786:Bone Substitutes; D011091:Polyesters; C515340:poly(epsilon-caprolactone)-b-poly(ethyleneglycol)-b-poly(epsilon-caprolactone); D011092:Polyethylene Glycols; D017886:Durapatite; D000469:Alkaline Phosphatase